Neos Therapeutics Inc. (NASDAQ:NEOS) was down 7.8% during mid-day trading on Wednesday . The company traded as low as $8.53 and last traded at $8.53, with a volume of 52,156 shares changing hands. The stock had previously closed at $9.25.

A number of equities research analysts recently issued reports on NEOS shares. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Thursday, April 21st. Royal Bank Of Canada lowered their price objective on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 17th. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Finally, BMO Capital Markets began coverage on Neos Therapeutics in a research note on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.75.

The firm’s 50-day moving average price is $9.77 and its 200-day moving average price is $10.08. The company’s market capitalization is $137.35 million.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Monday, May 16th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.08. On average, equities research analysts expect that Neos Therapeutics Inc. will post ($4.88) earnings per share for the current fiscal year.

In other Neos Therapeutics news, Director Gregory J. Robitaille acquired 7,442 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The shares were bought at an average cost of $7.55 per share, with a total value of $56,187.10. Following the completion of the transaction, the director now directly owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Juergen Martens acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were acquired at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at $99,000. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP raised its stake in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.